Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome
Language English Country United States Media print-electronic
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
PubMed
23386221
DOI
10.1002/mus.23657
Knihovny.cz E-resources
- MeSH
- Antiphospholipid Syndrome complications pathology MeSH
- Blepharoptosis etiology MeSH
- Stroke etiology MeSH
- Diplopia etiology MeSH
- Adult MeSH
- Fatal Outcome MeSH
- Castleman Disease complications pathology MeSH
- Humans MeSH
- Myasthenia Gravis complications pathology MeSH
- Abdominal Neoplasms pathology MeSH
- Neurologic Examination MeSH
- Pemphigus complications pathology MeSH
- Tomography, X-Ray Computed MeSH
- Muscle Weakness etiology MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
INTRODUCTION: Myasthenia gravis is an autoimmune disease marked by neuromuscular transmission failure at the neuromuscular junction. Castleman disease is a rare lymphoproliferative disease characterized by non-cancerous angiofolicular hyperplasia of lymphatic tissue. METHODS AND RESULTS: We describe a young man with rapid, successive manifestations of myasthenia gravis, a solitary form of Castleman disease, pemphigus vulgaris, and anti-phospholipid syndrome, which resulted in 2 ischemic cerebrovascular events that caused a severe central neurological deficit. DISCUSSION: We were unable to find a similar case in the literature, but we hypothesize that the temporal concidence of these clinical entities may be related to a common immunological pathway, such as B-cell activation. Therefore, we treated the patient with an immunosuppressant and anticoagulant treatment, as well as rituximab, a monoclonal antibody therapy against CD20+.
References provided by Crossref.org
